Dual quantification of dapivirine and maraviroc in cervicovaginal secretions from ophthalmic tear strips and polyester-based swabs via liquid chromatographic-tandem mass spectrometric (LC-MS/MS) analysis

被引:19
作者
Parsons, Teresa L. [1 ]
Emory, Joshua F. [1 ]
Seserko, Lauren A. [1 ]
Aung, Wutyi S. [1 ]
Marzinke, Mark A. [1 ,2 ]
机构
[1] Johns Hopkins Univ, Dept Med, Baltimore, MD 21287 USA
[2] Johns Hopkins Univ, Dept Pathol, Baltimore, MD 21287 USA
基金
美国国家卫生研究院;
关键词
Dapivirine; Maraviroc; Cervicovaginal fluid; Validation; Antiretroviral; VAGINAL MICROBICIDE GEL; ANTIRETROVIRAL DRUGS; PHARMACOKINETICS; SAFETY; DELIVERY; CCR5; PREEXPOSURE; VALIDATION; RESISTANCE; HEALTHY;
D O I
10.1016/j.jpba.2014.06.018
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Background: Topical microbicidal agents are being actively pursued as a modality to prevent HIV viral transmission during sexual intercourse. Quantification of antiretroviral agents in specimen sources where antiviral activity is elicited is critical, and drug measurements in cervicovaginal fluid can provide key information on local drug concentrations. Two antiretroviral drugs, dapivirine and maraviroc, have gained interest as vaginal microbicidal agents, and rugged methods are required for their quantification in cervicovaginal secretions. Methods: Cervicovaginal fluid spiked with dapivirine and maraviroc were applied to ophthalmic tear strips or polyester-based swabs to mimic collection procedures used in clinical studies. Following sample extraction and the addition of isotopically labeled internal standards, samples were subjected to liquid chromatographic-tandem mass spectrometric (LC-MS/MS) analysis using a Waters BEH C8, 50 mm x 2.1 mm, 1.7 mu m particle size column, on an API 4000 mass analyzer operated in selective reaction monitoring mode. The method was validated according to FDA Bioanalytical Method Validation guidelines. Results: Due to the disparate saturation capacity of the tested collection devices, the analytical measuring ranges for dapivirine and maravirocin cervicovaginal fluid on the ophthalmic tear strip were 0.05-25 ng/tear strip, and 0.025-25 ng/tear strip, respectively. As for the polyester-based swab, the analytical measuring ranges were 0.25-125 ng/swab for dapivirine and 0.125-125 ng/swab for maraviroc. Dilutional studies were performed for both analytes to extended ranges of 25,000 ng/tear strip and 11,250 ng/swab. Standard curves were generated via weighted (1/x(2)) linear or quadratic regression of calibrators. Precision, accuracy, stability and matrix effects studies were all performed and deemed acceptable according to the recommendations of the FDA Bioanalytical Method Validation guidelines. Conclusions: A rugged LC-MS/MS method for the dual quantification of dapivirine and maraviroc in cervicovaginal fluid using two unique collection devices has been developed and validated. The described method meets the criteria to support large research trials. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:407 / 416
页数:10
相关论文
共 36 条
[1]  
[Anonymous], ASPIRE STUD PREV INF
[2]  
[Anonymous], 2001, Guidance for industry, bioanalytical method validation
[3]  
[Anonymous], 2012, GLOBAL REPORT UNAIDS
[4]   The Safety, Persistence, and Acceptability of an Antiretroviral Microbicide Candidate UC781 [J].
Bunge, Katherine ;
Macio, Ingrid ;
Meyn, Leslie ;
Noguchi, Lisa ;
Parniak, Michael A. ;
Schwartz, Jill L. ;
Moncla, Bernard ;
Hillier, Sharon .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2012, 60 (04) :337-343
[5]   Impact of antiretroviral dosing frequency and pill burden on adherence among newly diagnosed, antiretroviral-naive HIV patients [J].
Buscher, A. ;
Hartman, C. ;
Kellen, M. A. ;
Giordano, T. P. .
INTERNATIONAL JOURNAL OF STD & AIDS, 2012, 23 (05) :351-355
[6]   Antiviral agents and HIV prevention: controversies, conflicts, and consensus [J].
Cohen, Myron S. ;
Muessig, Kathryn E. ;
Smith, M. Kumi ;
Powers, Kimberly A. ;
Kashuba, Angela D. M. .
AIDS, 2012, 26 (13) :1585-1598
[7]   Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis [J].
Dumond, Julie B. ;
Yeh, Rosa F. ;
Patterson, Kristine B. ;
Corbett, Amanda H. ;
Jung, Byung Hwa ;
Rezk, Naser L. ;
Bridges, Arlene S. ;
Stewart, Paul W. ;
Cohen, Myron S. ;
Kashuba, Angela D. M. .
AIDS, 2007, 21 (14) :1899-1907
[8]   Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract [J].
Else, Laura J. ;
Taylor, Stephen ;
Back, David J. ;
Khoo, Saye H. .
ANTIVIRAL THERAPY, 2011, 16 (08) :1149-1167
[9]   Development and bioanalytical validation of a liquid chromatographic-tandem mass spectrometric (LC-MS/MS) method for the quantification of the CCR5 antagonist maraviroc in human plasma [J].
Emory, Joshua F. ;
Seserko, Lauren A. ;
Marzinke, Mark A. .
CLINICA CHIMICA ACTA, 2014, 431 :198-205
[10]   Subgroup analyses of Maraviroc in previously treated R5 HIV-1 infection [J].
Faetkenheuer, Gerd ;
Nelson, Mark ;
Lazzarin, Adriano ;
Konourina, Irina ;
Hoepelman, Andy I. M. ;
Lampiris, Harry ;
Hirschel, Bernard ;
Tebas, Pablo ;
Raffi, Francois ;
Trottier, Benoit ;
Bellos, Nicholaos ;
Saag, Michael ;
Cooper, David A. ;
Westby, Mike ;
Tawadrous, Margaret ;
Sullivan, John F. ;
Ridgway, Caroline ;
Dunne, Michael W. ;
Felstead, Steve ;
Mayer, Howard ;
van der Ryst, Elna .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (14) :1442-U46